Viking Therapeutics (VKTX) Return on Capital Employed (2016 - 2025)
Historic Return on Capital Employed for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to 0.36%.
- Viking Therapeutics' Return on Capital Employed fell 2200.0% to 0.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36%, marking a year-over-year decrease of 2200.0%. This contributed to the annual value of 0.25% for FY2024, which is 1600.0% up from last year.
- Per Viking Therapeutics' latest filing, its Return on Capital Employed stood at 0.36% for Q3 2025, which was down 2200.0% from 0.26% recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Return on Capital Employed ranged from a high of 0.13% in Q2 2024 and a low of 0.52% during Q1 2023
- Over the past 5 years, Viking Therapeutics' median Return on Capital Employed value was 0.26% (recorded in 2025), while the average stood at 0.28%.
- Per our database at Business Quant, Viking Therapeutics' Return on Capital Employed plummeted by -2200bps in 2022 and then surged by 3400bps in 2024.
- Over the past 5 years, Viking Therapeutics' Return on Capital Employed (Quarter) stood at 0.27% in 2021, then plummeted by -81bps to 0.48% in 2022, then soared by 41bps to 0.28% in 2023, then surged by 40bps to 0.17% in 2024, then crashed by -115bps to 0.36% in 2025.
- Its last three reported values are 0.36% in Q3 2025, 0.26% for Q2 2025, and 0.2% during Q1 2025.